Watching for data coming
$Sensei Biotherapeutics(SNSE.US$ • There have been no dose limiting toxicities (DLT) observed across both the monotherapy and the combination arms.
• Sensei will present topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.
• Title: Initial results from a first-in-human phase 1 study of SNS-101 (pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors
• Presenter: Dr. Shiraj Sen
• Session Type: Poster Session
• Session Title: Developmental Therapeutics—Immunotherapy
• Date and Time: Saturday, June 1, 2024, at 9:00 a.m. – 12:00 p.m. CDT
• Sensei will present topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.
• Title: Initial results from a first-in-human phase 1 study of SNS-101 (pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors
• Presenter: Dr. Shiraj Sen
• Session Type: Poster Session
• Session Title: Developmental Therapeutics—Immunotherapy
• Date and Time: Saturday, June 1, 2024, at 9:00 a.m. – 12:00 p.m. CDT
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
